PMID- 35117930
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220205
IS  - 2219-6803 (Electronic)
IS  - 2218-676X (Print)
IS  - 2218-676X (Linking)
VI  - 9
IP  - 9
DP  - 2020 Sep
TI  - Primary synovial sarcoma of the duodenal bulb: a case report and review of the 
      literature.
PG  - 5663-5673
LID - 10.21037/tcr-20-1107 [doi]
AB  - Primary synovial sarcoma of the duodenal bulb is a rare mesenchymal tumor with 
      special morphological features. It usually originates from the major joints or 
      tendon sheaths of the extremities and mostly seen in young population, but rarely 
      found in gastrointestinal tract. In this manuscript, we reported the first case 
      of synovial sarcoma arising between the intestinal wall of the duodenal bulb with 
      a concomitant SYT/SSX type of the t(X;18) translocation. A 49-year-old male 
      presented to our hospital with a 2-month history of upper abdominal pain along 
      with a 4-day amply jaundice. Tumor marker testing showed only a slight increase 
      of carbohydrate antigen 19-9 (CA19-9). A computed tomography scan of his abdomen 
      showed that indeterminate tissue occupied the duodenal bulb wall, compressed the 
      surrounding tissues, and measured roughly 5.0 cm x 7.7 cm x 8.7 cm. Since the 
      sarcoma grows between the intestinal wall, which cannot be detected by endoscopy, 
      an initial diagnosis of duodenal wall stromal tumor was made at that time. 
      Postoperative Immunohistochemistry results showed that the tumor was positive for 
      the expression of transducin-like enhancer of split 1, B-cell lymphoma 2, and 
      Vimentin. These pathological findings were indicative of the diagnosis of 
      synovial sarcoma, but still did not provide sufficient diagnostic evidence. 
      Finally we confirmed the diagnosis by using fluorescence in situ hybridization 
      (FISH) with detection of the t(X;18) (SYT-SSX) translocation. No such lesions 
      were found on preoperative examination, so a diagnosis of primary duodenal 
      synovial sarcoma was made. After literature review, we found four reports of 
      duodenal synovial sarcomas, all of which could be detected endoscopically, but 
      there were no results of long-term follow-up. This case is the first reported 
      case of synovial sarcoma arising between the intestinal walls of the duodenal 
      bulb treated twice with ifosfamide and followed up for 13 months without 
      recurrence.
CI  - 2020 Translational Cancer Research. All rights reserved.
FAU - Yang, Hanteng
AU  - Yang H
AD  - Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, 
      China.
FAU - Cheng, Xiaocheng
AU  - Cheng X
AD  - Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, 
      China.
FAU - Zhu, Wei
AU  - Zhu W
AD  - Department of Pathology, Lanzhou University Second Hospital, Lanzhou, China.
FAU - Xiao, Jingying
AU  - Xiao J
AD  - Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, 
      China.
FAU - Li, Fan
AU  - Li F
AD  - Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, 
      China.
FAU - Ren, Yanxian
AU  - Ren Y
AD  - Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, 
      China.
FAU - Wang, Keshen
AU  - Wang K
AD  - Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, 
      China.
FAU - Jiao, Zuoyi
AU  - Jiao Z
AD  - Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, 
      China.
FAU - Luo, Changjiang
AU  - Luo C
AD  - Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, 
      China.
LA  - eng
PT  - Case Reports
PL  - China
TA  - Transl Cancer Res
JT  - Translational cancer research
JID - 101585958
PMC - PMC8799197
OTO - NOTNLM
OT  - Synovial sarcoma
OT  - duodenal bulb
OT  - fluorescence in situ hybridization
OT  - immunohistochemistry
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/tcr-20-1107). The authors have no 
      conflicts of interest to declare.
EDAT- 2020/09/01 00:00
MHDA- 2020/09/01 00:01
PMCR- 2020/09/01
CRDT- 2022/02/04 05:52
PHST- 2020/02/20 00:00 [received]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2022/02/04 05:52 [entrez]
PHST- 2020/09/01 00:00 [pubmed]
PHST- 2020/09/01 00:01 [medline]
PHST- 2020/09/01 00:00 [pmc-release]
AID - tcr-09-09-5663 [pii]
AID - 10.21037/tcr-20-1107 [doi]
PST - ppublish
SO  - Transl Cancer Res. 2020 Sep;9(9):5663-5673. doi: 10.21037/tcr-20-1107.